- Abstract
Objective
This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)/serotonin–noradrenaline reuptake inhibitor (SNRI) monotherapy.
Stuart A Montgomery et al., Hum Psychopharmacol. 2014 Sep; 29(5): 470–482.
Published online 2014 Aug 4. doi: 10.1002/hup.2424